Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mark Estabrook"'
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 31, Iss , Pp S12-S13 (2022)
Externí odkaz:
https://doaj.org/article/5734e5f513ea4663b81bcbba6eefd2dd
Autor:
Mark Estabrook, Krystyna M. Kazmierczak, Mark Wise, Francis F. Arhin, Gregory G. Stone, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 316-320 (2021)
Objectives: While aztreonam-avibactam is a potent β-lactam-β-lactamase-inhibitor combination, reduced in vitro activity against some Enterobacterales isolates has been reported. In this study, globally collected clinical isolates of Enterobacterale
Externí odkaz:
https://doaj.org/article/d80eb9b97bcb483c88e8e80466527753
The objective of this study was to describe the frequency of resistance determinants in meropenem-nonsusceptible (MEM-NS) Enterobacterales isolates collected in 2018 and 2019 as a part of the ATLAS global surveillance program. Among a total of 39,368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e717acc4820f1cedd36d588b46527cab
https://biblio.vub.ac.be/vubir/epidemiology-of-resistance-determinants-identified-in-meropenemnonsusceptible-enterobacterales-collected-as-part-of-a-global-surveillance-study-2018-to-2019(7fdee994-b89a-4040-988b-4115b5e8602f).html
https://biblio.vub.ac.be/vubir/epidemiology-of-resistance-determinants-identified-in-meropenemnonsusceptible-enterobacterales-collected-as-part-of-a-global-surveillance-study-2018-to-2019(7fdee994-b89a-4040-988b-4115b5e8602f).html
Publikováno v:
Open Forum Infectious Diseases. 9
Background The rapid spread of antimicrobial resistance among clinically isolated Enterobacterales (Eba) continues to threaten public health. Aztreonam (ATM) is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs) and avibactam (AVI) inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7b0b480e76f418d74801bc6b486b1b7
https://doi.org/10.1093/ofid/ofac492.1347
https://doi.org/10.1093/ofid/ofac492.1347
Publikováno v:
Open Forum Infectious Diseases. 9
Background Avibactam (AVI) is a β-lactamase inhibitor with potent inhibitory activity against Class A, Class C, and some Class D serine β-lactamases. The use of ceftazidime (CAZ) with AVI is approved for several indications. This study evaluated th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::407cc7d95daf433c363d23372563e44c
https://doi.org/10.1093/ofid/ofac492.1349
https://doi.org/10.1093/ofid/ofac492.1349
Publikováno v:
Open Forum Infectious Diseases. 9
Background β-lactamase-producing Enterobacterales (Eba) frequently carry resistance mechanisms for multiple drug classes, limiting treatment options. Avibactam (AVI) inhibits class A, class C, and some class D serine β-lactamases, while aztreonam (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b28b1c6ea71fb326c8879b720d9f0e15
https://doi.org/10.1093/ofid/ofac492.1350
https://doi.org/10.1093/ofid/ofac492.1350
Autor:
Sibylle Lob, Mark Estabrook, Wei-Ting Chen, Fakhar Siddiqui, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Imipenem/relebactam (IMR) is a combination of imipenem/cilastatin with the β-lactamase inhibitor relebactam, an inhibitor of class A and C β-lactamases. We evaluated the activity of IMR and comparators against AmpC- and extended-spectrum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c1bfd51878fb7239fb4f2e4559fd2ae
https://doi.org/10.1093/ofid/ofac492.1348
https://doi.org/10.1093/ofid/ofac492.1348
Autor:
Daniel F. Sahm, Mark Estabrook, Mark G. Wise, Gregory G. Stone, Krystyna M. Kazmierczak, Francis F. Arhin
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss, Pp 316-320 (2021)
Objectives: While aztreonam-avibactam is a potent β-lactam-β-lactamase-inhibitor combination, reduced in vitro activity against some Enterobacterales isolates has been reported. In this study, globally collected clinical isolates of Enterobacterale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c35452ef28534b5ec3a6d1cc88b683
https://doi.org/10.1016/j.jgar.2021.01.010
https://doi.org/10.1016/j.jgar.2021.01.010
Publikováno v:
Journal of Clinical Microbiology. 52:4049-4052
Ceftolozane MIC 50 /MIC 90 s were 4/8 μg/ml when tested against 26 CTX-M-14-type-producing isolates and 64/>64 μg/ml against 219 CTX-M-15-type-producing isolates. The addition of 4 μg/ml tazobactam lowered the ceftolozane MIC 50 /MIC 90 s to ≤0.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72e94c743615c1b39cd2da0bbd048ae7
https://doi.org/10.1128/jcm.02357-14
https://doi.org/10.1128/jcm.02357-14
Publikováno v:
Open Forum Infectious Diseases. 5:S732-S733
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8637835c1ac2dfc7fb3844b999b15b2
https://doi.org/10.1093/ofid/ofy210.2101
https://doi.org/10.1093/ofid/ofy210.2101